Of note, although these mutations are uncommon in prostate cancer, data suggest that patients with somatic BRCA1/2m will respond to PARPi.27 The efficacy of PARPi for advanced BC with somatic BRCA1/2m is currently being investigated in a study by the Translational Breast Cancer Research Consortium (NCT03344965). Here, BRCA1 is linked to breast cancer.